Detalles de la búsqueda
1.
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
N Engl J Med
; 372(12): 1114-25, 2015 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-25785969
2.
Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
Clin Infect Dis
; 65(5): 787-795, 2017 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29017280
3.
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
J Infect Dis
; 212(1): 18-27, 2015 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25395187
4.
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
Pediatr Blood Cancer
; 62(8): 1427-36, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25810327
5.
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico.
Rev Panam Salud Publica
; 33(6): 414-21, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23939366
6.
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
Antimicrob Agents Chemother
; 53(2): 401-11, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18936191
7.
Evaluation of cellular immune responses in subjects chronically infected with HIV type 1.
AIDS Res Hum Retroviruses
; 23(1): 67-76, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17263635
8.
Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Vaccine
; 34(30): 3454-62, 2016 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-27155493
9.
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 given to healthy infants at 2, 3, 4 and 12 months of age.
Pediatr Infect Dis J
; 34(2): 180-5, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25126854
10.
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
AIDS
; 29(11): 1345-54, 2015 Jul 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-25888646
11.
A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.
Vaccine
; 33(15): 1846-54, 2015 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-25707693
12.
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
Vaccine
; 33(14): 1719-25, 2015 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25698485
13.
Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures.
AIDS
; 17(13): 1933-9, 2003 Sep 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-12960826
14.
Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses.
Hum Gene Ther
; 14(10): 1017-34, 2003 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12869219
15.
3'-Tetrahydrofuranylglycine as a Novel, Unnatural Amino Acid Surrogate for Asparagine in the Design of Inhibitors of the HIV Protease.
J Am Chem Soc
; 115(2): 801-803, 1993 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30364398
16.
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
Vaccine
; 32(20): 2364-74, 2014 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-24606865
17.
Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
Hum Vaccin Immunother
; 10(5): 1343-53, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24576885
18.
13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine.
Pediatr Infect Dis J
; 33(2): 183-9, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24136369
19.
The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial.
Pediatr Infect Dis J
; 32(3): 257-63, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23001026
20.
Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries.
Vaccine
; 31(45): 5289-95, 2013 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-23973321